XRCC4 and neoplasm: We also demonstrated that knockdown of XRCC4 or treatment of the JNK inhibitor decreased cisplatin-resistant tumor growth in the xenograft mouse models, implying the clinical translation of targeting the cJUN-XRCC4 pathway in overcoming cisplatin resistance.